Skip to main content
Apply for Grants

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (176${count})

  • Cognition Biomarkers, 2014
    miRNA Markers of Cognition

    Objective/Rationale:
    In previous MJFF-funded research, these researchers identified four promising microRNAs (which regulate gene expression) associated with cognitive status. They profiled the miRNAs...

  • Improved Biomarkers and Clinical Outcome Measures, 2019
    Correlating MRI, Pathology and Cognitive Assessments toward Biomarkers of Cognitive Decline

    Study Rationale:
    Parkinson’s studies are working to identify magnetic resonance imaging (MRI) biomarkers for early diagnosis, disease severity and progression. However, attempts to explore how brain...

  • Cognitive Deficits and Mood Disorders in Parkinson's Disease, 2008
    Validating the Montreal Cognitive Assessment for the Diagnosis of Mild Cognitive Impairment in Parkinson's Disease

    Objective/Rationale:
    Dementia affects up to 80 percent of Parkinson’s disease patients, and the prevalence of other dementias including Alzheimer’s disease is high in this age group. A need exists for...

  • Cognitive Deficits and Mood Disorders in Parkinson's Disease, 2008
    Cognitive Decline in Parkinson's Disease

    Objective/Rationale:
    There are many studies on cognitive and behavioral alterations in Parkinson’s disease, but each of these investigations brought only a small piece of a large puzzle. Consequently...

  • Fall 2021 RFA: Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research, 2022
    Multiculturalism, Reported Cognitive Complaints and Predictors of Cognitive Decline Following Deep Brain Stimulation

    Study Rationale: Cognitive decline is common in people with Parkinson’s disease (PD), and changes in thinking and performance on objective cognitive tests reported by individuals and their family are...

  • Repositioning Drugs for PD, 2012
    Atomoxetine for Cognitive Impairment in Parkinson’s Disease

    Objective/Rationale:
    Parkinson’s disease (PD) causes well known motor symptoms of tremor, slowness and stiffness, but also leads to cognitive impairment. Research has shown that early loss of cells in...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.